Arbutus Biopharma opened lower at $3.86, compared with its previous close of $3.88. In the last trading session, the stock traded between $3.81 and $4.08. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Arbutus Biopharma is now worth
$ 116.28
Giving a profit of
$ 16.28 (16.28%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
+$0.16 (+3.99%)
Day High
$4.08
Day Low
$3.81
Day Open
$3.86
Prev Close
$3.88
Volume
33,85,179
1W Return
-0.74%
1M Return
-2.89%
3M Return
-13.69%
6M Return
-8.09%
1Y Return
-14.33%
Fundamentals
Market Cap ($ Mn)
619
PE Ratio
6.42
PB Ratio
3.87
PEG Ratio
-
ROE
-40.51%
ROCE
-38.00%
EPS (TTM)
$0.30
Investment Returns
1 Week
-0.74%
1 Month
-2.89%
3 Months
-13.69%
6 Months
-8.09%
9 Months
-3.00%
Financials
Quarterly
All values in $ Mn
10.7
Jun 25
0.5
Sep 25
1.1
Dec 25
179.1
Mar 26
1.0
Jun 26
0.3
Sep 26
Updates
10Nov
Arbutus Biopharma Q3 Results: EPS beats estimate, sales miss forecast
EPS of $0.30 beat consensus estimate of $(0.03) by 1100%. Quarterly sales of $299.000 thousand missed estimates by 78.46%. Revenue declined 43.48% YoY from $529.000 thousand. Earnings improved from a loss of $(0.04) per share in the prior year.
2 days ago
22Oct
FDA lifts three-year clinical hold on Arbutus Biopharma's AB-101
FDA lifted the clinical hold on Arbutus Biopharma's AB-101 IND application. Hold was initially placed in April 2023, pausing development for over three years. Phase 1 data showed high receptor occupancy in seven cHBV patients. Company plans up to $230 million stock buyback funded by Moderna settlement.
Arbutus Biopharma launched a US$230 million Dutch auction tender offer for its common shares. The repurchase price range is set between US$5.00 and US$5.75 per share. The offer expires on September 29, 2026, unless extended or terminated earlier. Funding for the buyback comes primarily from a recent US$178 million Moderna settlement.
Arbutus Biopharma’s Q2 results show a mixed bag: EPS of $(0.03) missed the $(0.02) estimate, while sales of $1.014 million beat the $700k forecast. However, sales dropped 90.56% YoY from $10.739 million, and EPS fell 400% from $0.01 in the prior year period.
3mo ago
16Jul
Arbutus files suits vs Pfizer, BioNTech to enforce LNP patents
Arbutus Biopharma Corporation and Genevant Sciences GmbH filed three international lawsuits against Pfizer Inc. and BioNTech SE to enforce LNP patents, seeking injunctions and damages. Arbutus received approximately $178M from Moderna Inc. related to a settlement agreement and expects a dividend from Genevant's parent in Q3 2026. The company plans to return up to approximately $230M in capital to shareholders pending board approval.
